Bernstein Initiates Coverage on Regeneron Pharmaceuticals Inc(NASDAQ:REGN). The shares have been rated Outperform. The rating by Bernstein was issued on Jun 29, 2016.
In a different note, On Apr 20, 2016, Wells Fargo said it Downgrades its rating on Regeneron Pharmaceuticals Inc. The shares have been rated ‘Market Perform’ by the firm. On Apr 4, 2016, Leerink Swann said it Maintains its rating on Regeneron Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $505.00 per share. The shares have been rated ‘Outperform’ by the firm. On Apr 4, 2016, Roth Capital said it Maintains its rating on Regeneron Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $555.00 per share. The shares have been rated ‘Buy’ by the firm.
Regeneron Pharmaceuticals Inc (REGN) made into the market gainers list on Fridays trading session with the shares advancing 2.65% or 9.27 points. Due to strong positive momentum, the stock ended at $358.5, which is also near the day’s high of $359.89. The stock began the session at $349 and the volume stood at 7,77,083 shares. The 52-week high of the shares is $605.9299 and the 52 week low is $329.09. The company has a current market capitalization of $37,671 M and it has 10,50,78,593 shares in outstanding.
Regeneron Pharmaceuticals Inc(REGN) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.20B. Analysts had an estimated revenue of $1.18B. Earnings per share were $2.57. Analysts had estimated an EPS of $2.61.
Several Insider Transactions has been reported to the SEC. On Jun 16, 2016, Sanofi (10% owner) purchased 64,731 shares at $364.22 per share price.Also, On May 25, 2016, Arthur F Ryan (director) sold 1,000 shares at $396.64 per share price.On May 19, 2016, Plew Daniel P Van (EVP & General Mgr Industrial O) sold 4,413 shares at $385.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.